HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Aug.18) - TCM Formula Granules VBP, Global Financing Rebound, CR Sanjiu

Pre-IPO BrainAurora Medical Technology - The Outlook Is Highly Uncertain

LianBio (LIAN.US) - Some Points Worth the Attention

Anti-Corruption in China Healthcare – the Impact and the Outlook

CanSino Biologics (6185.HK/​688185.CH) - The Story Has Changed

Hygeia Healthcare Group (6078.HK) - The Crack in the Egg

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<ul>
<li>Recent share-price declines in healthcare is mainly related to anti-corruption campaigns. Here're some updates.We recommend investors not to rush to buy the dip, but wait for the bottom.</li>
<li>We recommend A-share healthcare companies to buy back shares/increase dividends, in which case, despite slowing growth, A-shares are still the RMB-asset with the greatest potential for increases in expected returns.</li>
<li>
<a href="https://www.smartkarma.com/entities/cansino-biologics-inc" target="_blank" data-smartkarma-citation="entities:27739:1" rel="noopener">CanSino Biologics (6185 HK)</a> has entered a Framework Agreement with AstraZeneca, but investors should not be overly optimistic about the short-term or even medium-term performance contribution brought by this cooperation.</li>
</ul>


Recent share-price declines in healthcare is mainly related to anti-corruption campaigns. Here're some updates.We recommend investors not to rush to buy the dip, but wait for the bottom.
We recommend A-share healthcare companies to buy back shares/increase dividends, in which case, despite slowing growth, A-shares are still the RMB-asset with the greatest potential for increases in expected returns.

CanSino Biologics (6185 HK) has entered a Framework Agreement with AstraZeneca, but investors should not be overly optimistic about the short-term or even medium-term performance contribution brought by this cooperation.


Shenzhen Mindray Bio-Medical Electronics (300760 CH)

China Healthcare Weekly (Aug11)-Anti-Corruption Update, Increase A-Share Shareholder Return, CanSino